Polymegathism as a biomarker of mitochondrial disorders

pp 1–2 | Cite as

Letter to the Editor

First Online: 13 March 2018

Received: 05 February 2018

Accepted: 07 March 2018

This is a preview of subscription content, to check access

Notes

JF: design, literature search, discussion, and first draft. SZ-M: literature search, discussion, and critical comments.

The authors declare that they have no conflicts of interest.

1.
Bakhoum MF, Wu WP, White EC et al. (2018) Mitochondrial A3243G mutation results in corneal endothelial polymegathism. Graefes Arch Clin Exp Ophthalmol doi: https://doi.org/10.1007/s00417-018-3914-z
2.
Finsterer J, Zarrouk-Mahjoub S (2017) Mitochondrial multiorgan disorder syndrome score generated from definite mitochondrial disorders. Neuropsychiatr Dis Treat 13:2569–2579CrossRefPubMedPubMedCentralGoogle Scholar
3.
Anbar M, Ammar H, Mahmoud RA. (2016) Corneal endothelial morphology in children with type 1 diabetes. J Diabetes Res 2016:7319047. doi: https://doi.org/10.1155/2016/7319047
4.
Rummelt V, Folberg R, Ionasescu V et al (1993) Ocular pathology of MELAS syndrome with mitochondrial DNA nucleotide 3243 point mutation. Ophthalmology 100:1757–1766CrossRefPubMedGoogle Scholar
5.
Poulton J, Finsterer J, Yu-Wai-Man P (2017) Genetic counselling for maternally inherited mitochondrial disorders. Mol Diagn Ther 21:419–429CrossRefPubMedGoogle Scholar
6.
Finsterer J, Bindu PS (2015) Therapeutic strategies for mitochondrial disorders. Pediatr Neurol 52:302–313CrossRefPubMedGoogle Scholar

1.Krankenanstalt RudolfstiftungViennaAustria
2.University of Tunis El Manar and Genomics Platform, Pasteur Institute of TunisTunisTunisia